Early recognition of rheumatoid arthritis (RA) in primary care can facilitate referral to specialty care for timely initiation of disease-modifying antirheumatic drug treatment. Primary care clinicians also play a key role in improving long-term outcomes by encouraging adherence and monitoring patients for extra-articular manifestations of RA and comorbidities. In this activity, an expert in rheumatology provides a case-based review of early recognition and today’s approach to management.
Image courtesy of Lester Miller, MD.
Interactive case study
After completing this activity, participants should be better able to:
- Assess patients for symptoms and signs of RA
- Identify standard and novel therapies for RA and their appropriate use in clinical practice
- Apply strategies to evaluate patients with RA for extra-articular manifestations and comorbidities
NPs and PAs
Joint Accreditation Statement
In support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ANCC Credit Designation
NP course advisor: Mary Knudtson, DNSc, NP, FAAN, University of California, Irvine, Irvine, California
Nursing contact hours: 1.00, which includes 1.00 hour of pharmacology credit
Practicing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until March 30, 2022. PAs should only claim credit commensurate with the extent of their participation.
PA course advisor: Lawrence Herman, DMSc, MPA, PA-C, University of Lynchburg, Lynchburg, Virginia
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.
This activity was developed from a series of programs cosupported by educational grants from Bristol-Myers Squibb; Genentech, a member of the Roche Group; Gilead Sciences, Inc.; Eisai; and Novo Nordisk Inc.
This activity is supported by an educational grant from Gilead Sciences, Inc.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.
All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose to the audience all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Dr Herman: consultant/speakers bureau: Novo Nordisk.
Mr Pope has no relevant financial relationships to disclose.
None of the members of the Planning Committee or PCE staff have any relevant relationships to disclose, except Dr Herman as noted above.
Participants wishing to earn CE/CME credit must:
- Read the content in its entirety
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 67%.
The estimated time to complete this activity is 1.00 hour.
Release date: March 31, 2021
Expiration date: March 30, 2022
© 2021 Practicing Clinicians Exchange. All Rights Reserved. 97320C-7C